SlateStone Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

SlateStone Wealth’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,386	Closed	-$304K	–	204
2022 Q1	$304K	Sell	3,386 -14,750	-81%	-$1.36M	0.07%	144
2021 Q4	$2.03M	Hold	18,136	–	–	0.43%	56
2021 Q3	$2.28M	Sell	18,136 -3,600	-17%	-$464K	0.52%	45
2021 Q2	$2.94M	Sell	21,736 -300	-1%	-$39.4K	0.67%	37
2021 Q1	$2.99M	Hold	22,036	–	–	0.74%	38
2020 Q4	$3.1M	Buy	22,036 +150	+0.7%	+$19.2K	0.77%	33
2020 Q3	$2.44M	Hold	21,886	–	–	0.53%	54
2020 Q2	$2.45M	Hold	21,886	–	–	0.55%	53
2020 Q1	$1.7M	Sell	21,886 -400	-2%	-$35.4K	0.48%	58
2019 Q4	$2.12M	Sell	22,286 -450	-2%	-$38.9K	0.48%	55
2019 Q3	$1.73M	Sell	22,736 -85	-0.4%	-$7.06K	0.51%	53
2019 Q2	$2M	Hold	22,821	–	–	0.56%	46
2019 Q1	$2.07M	Buy	22,821 +835	+4%	+$71K	0.63%	37
2018 Q4	$1.58M	Buy	+21,986	New	+$1.77M	0.73%	38

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

SlateStone Wealth's XBI Position: Q2 2022 in Review

SlateStone Wealth sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 3,386 shares — an estimated $304K sold.

SlateStone Wealth first reported a position in XBI in Q4 2018 and held it in 14 quarters. The position peaked at $3.1M in Q4 2020. 704 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

SlateStone Wealth reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
SlateStone Wealth sold 3,386 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $304K.
SlateStone Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and held it in 14 quarters.
SlateStone Wealth's State Street SPDR S&P Biotech ETF position peaked at $3.1M in Q4 2020.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on SlateStone Wealth's 13F filing for Q2 2022, filed 4 Aug 2022.